Publications by authors named "Jillian R Mann"
Background: Following promising results to increase survival and reduce treatment burden in intracranial non-germinomatous germ cell tumors (NGGCTs), we conducted a European study using dose-intense chemotherapy followed by risk-adapted radiotherapy.
Methods: All patients received 4 courses of cisplatin/etoposide/ifosfamide. Non-metastatic patients then received focal radiotherapy only (54 Gy); metastatic patients received 30 Gy craniospinal radiotherapy with 24 Gy boost to primary tumor and macroscopic metastatic sites.
Article Synopsis
- The article outlines key features, treatment options, and relapse risks for children with mature teratoma (MT) and immature teratoma (IT) to guide future care plans.
- The study involved 351 patients under 16 years who had confirmed extracranial MT and IT; treatments included surgical excision and monitoring for potential malignant recurrence, with various chemos listed for specific relapses.
- Results showed high 5-year survival rates, but poorer outcomes were associated with incomplete surgical resection, tumor rupture, and certain tumor sites, underscoring the importance of careful surgical intervention and monitoring.
Epigenetic inactivation of RASSF1A, a putative tumor suppressor with proapoptotic activity, is frequently observed in a number of solid tumors, including a variety of epithelial cancers, but has not been described in hematopoietic tumors. We have analysed the expression and methylation status of RASSF1A in Hodgkin's lymphoma (HL)-derived cell lines, primary HL tumors and serum samples from HL patients. RASSF1A transcription was detectable in only 2/6 HL cell lines.
View Article and Find Full Text PDFThe European Board of Paediatrics has recommended for all paediatricians a three-year Common Trunk training in basic paediatrics, followed for tertiary care specialists, by three years of training in the relevant specialty. Paediatric Haematology and Oncology is a complex specialty with a broad range of activities, ranging from the care of children with leukaemia and solid tumours including those of the central nervous system, to all types of non-malignant haematologic disorders and laboratory haematology pursuits. A modular training programme has been recommended to provide a broad standard of training across the whole specialty which should last at least 18 months, and a further period of 18 months that may be used flexibly to prepare trainees for their anticipated future careers.
View Article and Find Full Text PDF